Executive Summary
This period's $4.99B in new federal contracts is dominated by VA and HHS awards totaling ~$2.7B (54%), signaling robust demand for healthcare services, medical evaluations, and biotech R&D amid long-term commitments to 2032. Bullish signals prevail (12/15) for public firms like L3Harris ($814M NASA space tech) and Lockheed Martin ($65M DHS engineering), with private players capturing bulk via full competition wins. Option-heavy structures (~$3B+ potential upside across contracts) offer multi-year revenue expansion, though firm-fixed-price prevalence flags execution risks.
Tracking the trend? Catch up on the prior New Federal Contractors digest from March 12, 2026.
Investment Signals(4)
- VA healthcare outsourcing surge(HIGH)▲
VA awards exceed $1.65B across 5 contracts for health insurance, medical evals, IT, and construction, with 95%+ outlays on key deals signaling immediate revenue.
- Space and defense tech stability(HIGH)▲
L3Harris secures $814M NASA engineering to 2029 with $216M outlayed; Lockheed adds $65M DHS C4ISR/sustainment to 2026, bolstering public defense revenue visibility.
- BARDA biotech R&D commitment(MEDIUM)▲
HHS/BARDA funds $980M+ in biotech R&D (MAPP $185M Ebola therapeutics, Advanced Tech $795M), with options up to $1.7B total and $100M+ outlays indicating pipeline momentum.
- IT services for fed agencies(HIGH)▲
$1B+ in IT/DevSecOps awards to Salient CRGT ($422M DEA), Cognosante ($245M VA), ThirdPacket ($64M CMS) via full competition, with $680M options upside.
Risk Flags(3)
- Execution[HIGH RISK]▼
Firm-fixed-price on 9/15 contracts (~$3.7B) exposes winners to cost overruns; short periods (e.g., TriWest 1-month) or $0 outlays (7/15) delay cash flow.
- Execution[MEDIUM RISK]▼
Long horizons to 2032 (8/15 contracts) heighten tech obsolescence, funding shifts; heavy subawards ($500M+ total) create dependencies.
- Competitive[MEDIUM RISK]▼
Full/open competition on 11/15 wins favors incumbents but pressures margins for non-set-aside renewals post-short terms.
Opportunities(3)
- ◆
$2.5B+ in unexercised options (e.g., Salient $454M, MAPP $722M, Cognosante $241M) enable 2x revenue scaling through 2028-2032.
- ◆
Set-aside wins for SDVOSB/8(a)/small biz ($400M+) in VA/HHS signal pipeline for similar firms in health/IT.
- ◆
Boeing indirect exposure via Insitu $96M UAS install to 2026; Lockheed follow-ons from sole-source DHS deals.
Sector Themes(3)
- ◆
$1.65B across insurance, evals, IT, EHR construction underscores outsourcing push.
- ◆
$980M R&D for viruses signals sustained HHS funding amid global risks.
- ◆
$220M+ engineering/IT for Coast Guard cutters, CBP amid border/space priorities.
Watch List(4)
- 👁
{"entity"=>"L3Harris Technologies", "reason"=>"$814M NASA to 2029 with $216M outlayed anchors space revenue; $19M options upside.", "trigger"=>"Q1 2026 outlay >$50M or NASA budget boost"}
- 👁
{"entity"=>"Lockheed Martin", "reason"=>"$65M DHS sole-source to 2026 despite $0 outlays; C4ISR sustainment positions for extensions.", "trigger"=>"outlay start or FY27 Coast Guard RFP win"}
- 👁
{"entity"=>"MAPP Biopharmaceutical", "reason"=>"$185M obligated/$906M options in BARDA antivirals to 2032; small biz scale-up potential.", "trigger"=>"option exercise >$200M"}
- 👁
{"entity"=>"Salient CRGT", "reason"=>"$422M DEA IT with $454M options to 2028; competitive strength in fed IT.", "trigger"=>"extension to 2028 or new GSA task orders"}
Get daily alerts with 4 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 15 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC